Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Joel Epstein

Pulmonary Disease Lakewood, CA Medical Doctor

NPI 1013037779 CMS profile 272638

3650 South St, Suite 308, Lakewood, CA 90712

Open in the dashboard

General payments

$4,722

238 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Joel Epstein of Lakewood, CA is reported in the CMS Open Payments database as having received $4,722 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $98 6
2022 General $339 15
2021 General $1,307 75
2020 General $1,130 60
2019 General $1,848 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Epstein
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Joel Epstein were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Joel Epstein Pulmonary Disease median Middle half National median
2019 $1,848 $377 $109–$1,340 $163
2020 $1,130 $230 $56–$907 $114
2021 $1,307 $269 $68–$1,072 $132
2022 $339 $390 $100–$1,457 $149
2023 $98 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,007 46 payments
  2. GlaxoSmithKline, LLC. $741 47 payments
  3. AstraZeneca Pharmaceuticals LP $712 38 payments
  4. Allergan Inc. $614 3 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $412 39 payments
  6. Mylan Specialty L.P. $400 22 payments
  7. Regeneron Healthcare Solutions, Inc. $171 6 payments
  8. Philips Electronics North America Corporation $107 6 payments
  9. Merck Sharp & Dohme Corporation $89 5 payments
  10. Genzyme Corporation $70 3 payments
  11. Other $398 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,127 236 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $583 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2019–2023
  1. OFEV $874 34 payments
  2. TRELEGY ELLIPTA $452 28 payments
  3. LifeVest $412 39 payments
  4. SYMBICORT $316 16 payments
  5. SPIRIVA RESPIMAT $285 16 payments
  6. Yupelri Respiratory and Allergy $229 14 payments
  7. BREZTRI $195 10 payments
  8. STIOLTO RESPIMAT $180 10 payments
  9. YUPELRI Anticholinergics, Inhaled $171 8 payments
  10. DUPIXENT $171 6 payments
  11. Other $1,776 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record